Number of shares and voting rights of Innate Pharma as of December 18, 2025
Innate Pharma releases its 2026 financial calendar
Number of shares and voting rights of Innate Pharma as of November 27, 2025
Innate Pharma to present at Jefferies Global Healthcare Conference
Innate Pharma reports Third Quarter 2025 business update and financial results
Innate Pharma announces FDA clearance to proceed with TELLOMAK 3, a confirmatory Phase 3 trial of lacutamab in CTCL
Innate Pharma announces conference call and webcast for Third quarter 2025 results and business updates
Innate Pharma to host analyst and investor event on lacutamab on October 28, 2025
Innate Pharma Reports First Half 2025 Business Update And Financial Results
Innate Pharma announces its participation in the 25th edition of the European Midcap Event
